Volume 14 - Issue 8 - August 2006

I was recently asked to write an editorial for the Journal of Dermatological Treatment regarding the manuscript,  “Prevention of chronic furunculosis with low-dose azithromycin.” In this case series, Aminzadeh, et al., successfully used once-weekly azithromycin to treat chronic furunculosis in 24 patients. However, with the rise of antibiotic resistance, especially community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), should dermatologists be more cautious regarding the drugs we choose to treat our patients? Moreover, are we contributing to